期刊
CLINICS IN LABORATORY MEDICINE
卷 37, 期 3, 页码 449-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cll.2017.06.001
关键词
Tumor; Melanoma; Immunology; T cell; Type 1; Checkpoint; Prognosis; Immunotherapy
The relatively high DNA mutational burden in melanoma allows for the creation of potentially foreign, immune-stimulating neoantigens, and leads to its exceptional immunogenicity. Brisk tumor-infiltrating lymphocytes, a marker of immune editing, confer improved overall survival in melanoma, possibly due to reduced sentinel lymph node spread. Meanwhile, T-cell-stimulating drugs, so-called T-cell checkpoint inhibitors, which reverse peripheral tolerance-dependent tumor escape, have demonstrated unparalleled clinical success in metastatic melanoma. Markers to predict response to immunotherapy are currently imperfect, and the subject of intense research, which will guide the future of ancillary pathologic testing in this setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据